Lyell Immunopharma Inc LYEL
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-17 |
| Shares Out. | 23,330,000 |
| Website | lyell.com/ ↗ |
| Phone | 13025310855 |
| Employees | 161 |
| Revenue | $4,000 |
| Gross Profit | $4,000 |
| Net Income | -$44.8M |
| Free Cash Flow | -$134.0M |
| Total Assets | $311.2M |
| Total Liabilities | $77.3M |
| Equity | $233.8M |
About Lyell Immunopharma Inc
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lyell Immunopharma Inc is a publicly traded company under the ticker symbol LYEL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-09-01)